Abstract

An international research team led by Lund University Diabetes Centre has discovered blood-based epigenetic markers that may help predict which people with type 2 diabetes are at risk of serious cardiovascular events. In a study of 752 newly diagnosed participants followed for just over seven years, a scoring tool based on DNA methylation patterns outperformed standard clinical risk calculators, particularly in ruling out low-risk individuals. While further validation is needed, this approach could lead to a simple blood test that supports more personalized prevention and treatment strategies in type 2 diabetes care.

Key Points

• Study Scope: Followed 752 newly diagnosed type 2 diabetes patients for an average of 4 years, identifying 102 major cardiovascular events.
• Main Finding: Developed a DNA methylation-based score using 87 sites that predicted heart risk more accurately than standard clinical risk scores.
• Low-Risk Identification: The tool had a 96% probability of correctly identifying those unlikely to develop cardiovascular disease.
• Limitations: Short follow-up period, limited diversity, moderate positive predictive value, and missing lifestyle data.
• Future Potential: Could evolve into a simple blood test to guide personalized prevention, treatment, and follow-up in type 2 diabetes.

Abstract

This post explains why I took medical courses to gain a deeper understanding of the clinical side of type 2 diabetes and obesity care. The insights gained help me better interpret the data, support public education, and present CGM and related metrics in a more informed way.

Key Points

• Medical coursework offered critical insight into diabetes and obesity care priorities.
• Understanding clinical perspectives shaped how I interpret CGM data.
• CME courses emphasized scientific integrity and commercial neutrality.
• These experiences support better health communication and patient education.
• Learning from clinicians strengthens how I present data to the public.

Abstract

A new study led by researchers at the University of Copenhagen and Karolinska Institutet reveals that insulin resistance varies widely between individuals, even among those with the same diagnosis. By analyzing muscle tissue from over 120 people, the team uncovered unique molecular "fingerprints" that could help detect insulin resistance earlier and guide more personalized treatments for type 2 diabetes. Professor Juleen Zierath, a pioneer in exercise and metabolic research and winner of the 2024 Diabetes Prize for Excellence, played a key role in the study. The findings highlight the importance of moving beyond one-size-fits-all approaches in diabetes care.

Key Points

• Researchers discovered unique molecular “fingerprints” in muscle that reveal how individuals respond to insulin.
• Insulin resistance varies widely, even among people with the same diagnosis.
• Some individuals with type 2 diabetes respond better to insulin than those without the condition.
• A human-specific muscle protein, AMPKγ3, may offer a new target for treatment.
• The findings support more personalized and earlier approaches to diabetes care.